Two Egis subsidiaries among the Best Employers in 2018

Egis Russia and Egis Polska have recently been recognized as Best Employers at Aon Hewitt’s Employee Engagement Survey. details >

All phases of Highly Potent drug development and production will be possible at Egis

Egis launches a project with a total value of EUR 22 million in its Production Site of Körmend. The investment - which has been granted subsidies on the basis of EUR 3.5 million individual government decision - allows the company to develop and manufacture Highly Potent (HP), typically oncology drugs in Körmend, Hungary as well as to increase the site’s production capacity by establishing a new packaging plant. details >

Egis is one of the winners of the Swedish Chamber of Commerce in Hungary’s Gran Prize for interdisciplinary innovations

Outstanding industrial innovations for sustainability were awarded on the 23th of May for the sixth time. This year, Egis has received the prize for a wastewater dehalogenation method. details >

Egis keeps growing in OTC markets via acquisition

Egis Pharmaceuticals PLC acquired Sinuforte, a nasal spray from Hartington Business S.L. Egis seeks to ensure its growing presence in major export markets, Russia and the CIS countries through organic growth and targeted acquisitions. details >

Egis intensifies its acquisition strategy in 2017

Egis Pharmaceuticals PLC has acquired Sorbifer’s product rights from AstraZeneca. The transaction reinforces Egis’ position on its key markets. details >

Egis is one of the most attractive workplaces in the pharma industry

Our company was awarded based on the evaluation of employees and job seekers. details >